title: Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study.
abstract: BACKGROUND
  The 2 Cohort randomised PrefHer trial examined the preferences of HER2+ve primary breast cancer patients for intravenous (IV) or subcutaneous (SC) delivery of trastuzumab via a Single Injectable Device (SID) or hand-held syringe (HHS). The novel approach and design of the study permitted an in-depth exploration of patients' experiences, the impact that different modes of delivery had on patients' well-being and implications for future management.
  
  
  METHODS
  The preferences, experiences and general comments of patients in the PrefHer study were collected via specific semi-structured interview schedules. Exploratory analyses of data were conducted using standard methodology. The final question invited patients to make further comments, which were divided into 9 thematic categories - future delivery, compliments, time/convenience, practical considerations, pain/discomfort, study design, side-effects, psychological impact, and perceived efficacy.
  
  
  RESULTS
  267/467 (57%) patients made 396 additional comments, 7 were neutral, 305 positive and 86 negative. The three top categories generating the largest number of comments were compliments and gratitude about staff and being part of PrefHer (75/396; 19%), the potential future delivery of SC trastuzumab (73/396; 18%), and practical considerations about SC administration (60/396; 15%).
  
  
  CONCLUSIONS
  Eliciting patient preferences about routes of administration of drugs via comprehensive interviews within a randomised cross-over trial yielded rich and important information. The few negative comments made demonstrated a need for proper staff training in SC administration Patients were grateful to have been part of the trial, and would have liked to continue with SC delivery. The possibility of home administration in the future also seemed acceptable.
  2010-024099-25.
authors.affiliation: Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, Brighton BN1 9RX, United Kingdom.
authors.forename: L
authors.initials: L
authors.lastname: Fallowfield
authors.affiliation: GMA Biometrics, F. Hoffmann-La Roche Ltd, Building 74, Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Osborne
authors.affiliation: Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, Brighton BN1 9RX, United Kingdom.
authors.forename: C
authors.initials: C
authors.lastname: Langridge
authors.affiliation: Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, Brighton BN1 9RX, United Kingdom.
authors.forename: K
authors.initials: K
authors.lastname: Monson
authors.affiliation: Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, Brighton BN1 9RX, United Kingdom.
authors.forename: J
authors.initials: J
authors.lastname: Kilkerr
authors.affiliation: Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, Brighton BN1 9RX, United Kingdom. Electronic address: val@sussex.ac.uk.
authors.forename: V
authors.initials: V
authors.lastname: Jenkins
mesh_terms: D061605:Administration, Intravenous / Q000523:psychology; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy*; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous / Q000523:psychology; D057240:Patient Preference / Q000523:psychology*; D017060:Patient Satisfaction; D000068878:Trastuzumab / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D000068878:Trastuzumab
keywords: Breast cancer; Drug administration; Patient preferences; Trastuzumab